Want to see IMA full AI Analyst Report?
IMA Stock Chart & Stats
$5.90
--
Market closed
$5.90
--
Day’s Range― - ―
52-Week Range$3.94 - $17.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$69.80M
Enterprise Value-$48.20
Total Cash (Recent Filing)$117.21M
Total Debt (Recent Filing)$8.15M
Price to Earnings (P/E)―
Beta0.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,279,130
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.00Price Target Upside120.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExtremely low debt and a sizable equity base provide durable financial flexibility for a pre-commercial biotech. With minimal interest burden and capacity to raise capital on better terms, the company can fund clinical programs and strategic initiatives without immediate solvency pressure, lengthening runway.
Advancing Phase 2 Clinical ProgramsProgression to and scaling of Phase 2 trials represents structural de-risking of the pipeline. Successful Phase 2 data would validate mechanisms, create partnering or licensing optionality, and materially alter long-term commercial prospects rather than a short-term market move.
Strengthened Financial Leadership (new CFO)Hiring an experienced biotech finance executive improves capital allocation, reporting discipline, and funding strategy at a critical development stage. This structural governance enhancement should reduce execution risk around financing, budgeting for trials, and interactions with investors and partners.
Bears Say
Sustained Large Cash BurnPersistent negative operating and free cash flow of ~-$52M TTM is a durable constraint requiring repeated external financing or partnerships. Continued burn increases dilution risk, pressures management to prioritize near-term financing over long-term strategy, and can limit the ability to fund multiple trials concurrently.
Pre-commercial, No Revenue BaseAbsence of recurring revenue leaves the company fully dependent on capital markets and milestone payments to sustain operations. Long-term viability hinges on trial success or partnerships; until commercialization, there's limited internal cash generation to offset clinical spend or absorb setbacks.
Recent Turnover In Finance/operationsLoss of a senior finance and operations executive during a financing-intensive development phase raises execution and oversight risks. Transition periods can delay budgeting, controls, and vendor/clinical operations coordination, potentially affecting trial timelines and capital planning stability.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $17.90 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $69.80M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,279,130 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (120.34% Upside)
$13.00 (120.34% Upside)
Insider Transactions
Sold Shares
Worth $17.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.47%
Trailing 12-Months
Company Description
ImageneBio
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
IMA Stock 12 Month Forecast
Average Price Target
$13.00
▲(120.34% Upside)
Technical Analysis
Ownership Overview
32.85% Insiders
3.60% Mutual Funds
39.73% Other Institutional Investors
20.77% Public Companies and
Individual Investors